Indeed, in humans, epidemiologic data suggest that SLFN11 expression is higher in patients with ovarian, lung, or breast cancer who respond to chemotherapy [67] and in patients with gastric carcinoma who survive longer [65]. This evidence concerns the gene SLFN11 and breast carcinoma.